Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.
wherein R
2
, R
3
R
4
, R
5
and R
6
are defined herein.
[EN] AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS<br/>[FR] MODULATEURS DE LXR À BASE D'AMINE OU DE (THIO) AMIDE
申请人:PHENEX FXR GMBH
公开号:WO2019016269A1
公开(公告)日:2019-01-24
The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXRα and/or LXRβ) and act preferably as inverse agonists of LXR.
本发明涉及公式(I)的衍生物,其结合到肝X受体(LXRα和/或LXRβ),并且作为LXR的拮抗剂。
HETEROARYLS AND USES THEREOF
申请人:Freeze Brian S.
公开号:US20120172345A1
公开(公告)日:2012-07-05
This invention provides compounds of formula IA-i-a or IB-i-a and subsets thereof:
wherein Z, HY, R
1
, R
2
, R
3
, G
1
, W, n, and A and subsets thereof are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
The present invention relates to a compound represented by the formula (I) or (I′):
wherein each symbol is as defined in the specification, or a salt thereof, and a PI3K and(or) mTOR inhibitor containing the compound or a prodrug thereof.
This invention provides compounds of formula IA or IB:
wherein R
1
, R
2
, G
1
and HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.